Chemed Corporation (CHE)
CHE (NYSE:Health Services)
$68.18
+1.51
+2.26%
Today's Range: 66.48 - 68.52 |
CHE Avg Daily Volume: 265,200
| Last Update: 05/17/13 - 4:01 PM EDT |
| Volume: 456,198 |
| YTD Performance: -0.60%
|
| Open: $66.49 |
| Previous Close: $66.67 |
| 52 Week Range: $54.06 -
$82.00 |
| Oustanding Shares: 18,868,108 |
| Market Cap: 1,257,936,760 |
6-Month Chart
TheStreet Ratings Grade for CHE
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
1 |
1 |
1 |
1 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
3 |
3 |
3 |
3 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
2.40 |
2.40 |
2.40 |
2.40 |
| Latest Dividend: |
0.18 |
| Latest Dividend Yield: |
1.08% |
| Dividend Ex-Date: |
02/28/13 |
| Price Earnings Ratio: |
14.10 |
|
| Price Earnings Comparisons: |
| CHE |
Sector Avg. |
S&P 500 |
| 14.10 |
14.10 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
-10.40%
|
20.35%
|
20.16%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
5.50 |
0.20 |
0.06 |
| Net Income |
3.90 |
0.21 |
0.06 |
| EPS |
12.70 |
0.43 |
0.13 |
| Earnings for CHE: |
| EBITDA |
0.20B |
| Revenue |
1.43B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.16 |
$1.18 |
$4.94 |
$5.28 |
| Number of Analysts |
1 |
1 |
1 |
1 |
| High Estimate |
$1.16 |
$1.18 |
$4.94 |
$5.28 |
| Low Estimate |
$1.16 |
$1.18 |
$4.94 |
$5.28 |
| Prior Year |
$1.18 |
$1.20 |
$5.04 |
$4.94 |
| Growth Rate (Year over Year) |
-1.69% |
-1.67% |
-1.98% |
6.88% |
| Mar 05, 2013 | 6:00 PM EST
Companies that provide end-of-life services have demographics on their side.
Feb 20, 2013 | 8:09 AM EST
Shares of CHE now seen reaching $91, Oppenheimer said. Fourth quarter beat. Outperform rating.
Oct 03, 2012 | 8:39 AM EDT
Shares of CHE now seen reaching $80, Oppenheimer said. Bullish following management meetings. Outperform rating.
| Apr 19, 2012 | 4:30 PM EDT
These stocks stand to benefit if Americans can accept the fact that rising health care costs aren't magically going away.
| Nov 18, 2011 | 9:00 AM EST
Recently accused of Medicare fraud, Chemed is facing costly legal problems.
| Oct 20, 2011 | 4:00 PM EDT
Financial pain caused by a flat yield curve will cascade from the insurance industry into health care.
| Sep 06, 2011 | 3:00 PM EDT
If only the entire economy felt as well.
